Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer

L M Forrest; D C McMillan; C S McArdle; W J Angerson; D J Dunlop

doi:10.1038/sj.bjc.6601789

Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer

Br J Cancer. 2004 May 4;90(9):1704-6. doi: 10.1038/sj.bjc.6601789.

Authors

L M Forrest¹, D C McMillan, C S McArdle, W J Angerson, D J Dunlop

Affiliation

¹ University Department of Surgery, Royal Infirmary, Glasgow G31 2ER, Scotland, UK.

Abstract

The value of an inflammation-based prognostic score (GPS) was compared with performance status (ECOG) in patients (n=109) receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. On multivariate analysis with ECOG, white cell count and the GPS entered as covariates, only the GPS was a significant independent predictor of survival (HR 1.88, 95% CI 1.25-2.84, P=0.002).

Publication types

Comparative Study

MeSH terms

Adult
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / blood*
C-Reactive Protein / analysis
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / mortality*
Carcinoma, Non-Small-Cell Lung / pathology
Female
Humans
Hypoalbuminemia / blood
Inflammation / blood*
Inflammation / pathology
Lung Neoplasms / drug therapy
Lung Neoplasms / mortality*
Lung Neoplasms / pathology
Male
Middle Aged
Platinum Compounds / therapeutic use*
Prognosis
Survival Analysis

Substances

Antineoplastic Agents
Biomarkers, Tumor
Platinum Compounds
C-Reactive Protein